Search results for abx831220

Urelumab, Abbexa, abx831220

Urelumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF9/CD137, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.